carmustine has been researched along with B16 Melanoma in 11 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), carboplatin, and camptothecin were incorporated into controlled-release polymers and tested individually against intracranial challenges with one of four tumors (lung carcinoma, renal cell carcinoma, colon carcinoma, and melanoma)." | 3.69 | Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. ( Anderson, RC; Babel, KM; Brat, DJ; Brem, H; Ewend, MG; Pinn, ML; Tabassi, K; Tyler, BM; Williams, JA, 1996) |
| "The effects on experimental melanoma of a combination of recombinant human tumour necrosis factor alpha (rhTNF alpha) and carmustine (BCNU) were studied in vitro and in vivo." | 1.28 | Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo. ( Gore, ME; Jones, AL; Lakhani, S; McElwain, TJ; Millar, BC; Millar, JL; Powell, B; Selby, P; Winkley, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roger, P | 2 |
| Monneret, C | 2 |
| Fournier, JP | 2 |
| Choay, P | 1 |
| Gagnet, R | 1 |
| Gosse, C | 2 |
| Letourneux, Y | 1 |
| Atassi, G | 2 |
| Gouyette, A | 3 |
| Ewend, MG | 1 |
| Williams, JA | 1 |
| Tabassi, K | 1 |
| Tyler, BM | 2 |
| Babel, KM | 1 |
| Anderson, RC | 1 |
| Pinn, ML | 1 |
| Brat, DJ | 1 |
| Brem, H | 2 |
| Poo, WJ | 1 |
| Guo, X | 1 |
| Haslund, B | 1 |
| Mozdziesz, DE | 1 |
| Feleszko, W | 1 |
| Zagozdzon, R | 1 |
| Jakobisiak, M | 1 |
| Ophir, R | 1 |
| Moalem, G | 1 |
| Pecht, M | 1 |
| Shashoua, M | 1 |
| Rashid, G | 1 |
| Ben-Efraim, S | 1 |
| Trainin, N | 1 |
| Burstein, Y | 1 |
| Keisari, Y | 1 |
| Sampath, P | 1 |
| Hanes, J | 1 |
| DiMeco, F | 1 |
| Brat, D | 1 |
| Pardoll, DM | 1 |
| Rissé, S | 1 |
| Ardouin, P | 1 |
| Finch, RA | 1 |
| Shyam, K | 1 |
| Penketh, PG | 1 |
| Sartorelli, AC | 1 |
| Jones, AL | 1 |
| Millar, JL | 1 |
| Millar, BC | 1 |
| Powell, B | 1 |
| Selby, P | 1 |
| Winkley, A | 1 |
| Lakhani, S | 1 |
| Gore, ME | 1 |
| McElwain, TJ | 1 |
| Dumont, P | 1 |
| Lin, TS | 1 |
| Prusoff, WH | 1 |
11 other studies available for carmustine and B16 Melanoma
| Article | Year |
|---|---|
Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
Topics: Amino Sugars; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Drug Evaluation, Precli | 1989 |
Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carboplatin; Carcinoma; Carcin | 1996 |
Immunomodulation and enhancement of antitumor activity by co-administration of 1,3-bis(2-chloroethyl)-1-nitrosourea and thymidine.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Carmustine; Female; Hypersensiti | 1997 |
Re: Greying of America will foster new strategies in oncology.
Topics: Aging; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 1998 |
THF-gamma 2-mediated reduction of pulmonary metastases and augmentation of immunocompetence in C57BL/6 mice bearing B16-melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Lung; Lung Neoplasms; L | 1999 |
Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Biodegradation, Environmental; B | 1999 |
Synthesis and antitumour activity of a new series of nitrosoureido sugars.
Topics: Animals; Antineoplastic Agents; Carmustine; Glucosides; Leukemia L1210; Melanoma, Experimental; Mice | 2000 |
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.
Topics: Animals; Antineoplastic Agents; Carmustine; Drug Screening Assays, Antitumor; Female; Humans; Hydraz | 2001 |
Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Drug Synergism; Female; Melanom | 1990 |
Characterization of the anti-tumour activity against solid tumours of a new nitrosoureido sugar: Cy 233.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Dose-Response Relatio | 1989 |
Enhancement of the anticancer activity of bis(2-chloroethyl)nitrosourea in mice by coadministration of 2'-deoxyuridine, 2'-deoxycytidine, or thymidine.
Topics: Animals; Carmustine; Deoxycytidine; Deoxyribonucleosides; Deoxyuridine; Drug Synergism; Leukemia L12 | 1987 |